Amneal Pharmaceuticals, Inc.

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 15:59:52 2024-05-29 EDT			5-day change	1st Jan Change
6.78 ^USD	-0.15%		+1.95%	+11.70%

05-22	Amneal Pharmaceuticals Begins Supplying Generic Version of Narcan	DJ
05-22	Amneal Begins Supplying Over-The-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	CI

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for Full Year 2024

May 03, 2024 at 06:00 am

Amneal Pharmaceuticals, Inc. affirmed earnings guidance for full year 2024. For the year, company expects Net revenue to be $2.55 billion - $2.65 billion.

Latest news about Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals Begins Supplying Generic Version of Narcan	05-22	DJ
Amneal Begins Supplying Over-The-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	05-22	CI
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	05-06	MT
Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	05-03	MT
Drugmaker Amneal agrees to $270 million U.S. opioid settlement	05-03	RE
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	05-03	MT
Transcript : Amneal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 03, 2024	05-03
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Climb	05-03	MT
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63	05-03	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M	05-03	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09	05-03	MT
North American Morning Briefing : Apple, Amgen -2-	05-03	DJ
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for Full Year 2024	05-03	CI
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	04-24	MT
Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray	04-24	DJ
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose	04-24	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	04-18	MT
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	04-17	CI
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	04-12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	04-12	MT
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	04-08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	04-08	MT
North American Morning Briefing : Inflation Data, -2-	04-08	DJ
Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination	03-25	DJ

Chart Amneal Pharmaceuticals, Inc.

Duration

Period

More charts

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Companyâs Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segmentâs portfolio includes central nervous system disorders (Parkinsonâs disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Companyâs AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Sector

Pharmaceuticals

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amneal Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.78 USD

Average target price

8.25 USD

Spread / Average Target

+21.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMNEAL PHARMACEUTICALS, INC.	+11.70%	2.09B
ELI LILLY AND COMPANY	+39.22%	731B
NOVO NORDISK A/S	+32.37%	586B
JOHNSON & JOHNSON	-7.85%	348B
MERCK & CO., INC.	+15.48%	319B
ABBVIE INC.	-0.12%	273B
ASTRAZENECA PLC	+13.32%	235B
NOVARTIS AG	+7.38%	202B
ROCHE HOLDING AG	-7.08%	203B
PFIZER, INC.	-3.37%	158B

Other Pharmaceuticals